Criteria for Transitioning Patients from Bispecific Therapy to Community Oncologist Care in Multiple Myeloma

Opinion
Video

Panelists discuss how determining a patient's readiness to transition back to community oncology care after bispecific therapy involves assessing multiple factors including treatment response, toxicity resolution, overall stability, and the community practice's capabilities.

Video content above is prompted by the following:

  • What criteria or thresholds do you use to determine when a patient is ready for transition back to the community oncologist after bispecific therapy? (e.g. time since treatment, resolution of toxicities, evidence of response)
  • How do social factors play into the referral process?
  • How do the AEs differ based on the class of bispecific? Which AEs are you seeing in practice?
  • How are they managed?
Recent Videos
4 KOLs are featured in this series.
4 KOLs are featured in this series.
4 KOLs are featured in this series.
9 Experts are featured in this series.
9 Experts are featured in this series.
2 experts are featured in this series.
Vinay K. Puduvalli, MD, is featured in this series.
9 Experts are featured in this series.
9 Experts are featured in this series.
Patients treated with BCMA-directed immunotherapies for myeloma may experience susceptibility to severe infections following treatment.
Related Content